Piper Sandler analyst David Westenberg initiated coverage with a Buy rating on Cytek Biosciences (CTKB – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $8.74.
According to TipRanks, Westenberg is a 3-star analyst with an average return of 2.1% and a 48.30% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Illumina, Myriad Genetics, and Natera.
Cytek Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $10.67, a 22.08% upside from current levels. In a report released today, TD Cowen also assigned a Buy rating to the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
CTKB market cap is currently $1.18B and has a P/E ratio of -84.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytek Biosciences (CTKB) Company Description:
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
Read More on CTKB:
- Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
- Cytek Biosciences Enhances Executive Severance Benefit Plan
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
